Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia

被引:22
作者
Kiem, Sungmin
Schentag, Jerome J.
机构
[1] SUNY Buffalo, Sch Pharm, Buffalo, NY 14260 USA
[2] CPL Associates LLC, Amherst, NY USA
关键词
susceptibility of antibiotics; pharmacokinetics/pharmacodynamics of antibiotics; area under the inhibitory concentration-time curve; ventilator-associated pneumonia;
D O I
10.1055/s-2006-933674
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) have been used as the most popular prediction tools for antimicrobial action, they have shortcomings. The MIC and MBC do not consider time-related antimicrobial effects, such as killing rate and postantibiotic effect. In this regard, the concept of pharmacokinetic and pharmacodynamic (PK/PD) modeling has been introduced to help interpret determinations of susceptibility breakpoints. Although area under the inhibitory concentration-time curve (AUIC) can be used as a universal PK/PD parameter, target magnitudes of the parameter have to be high enough to exert rapid bactericidal activity (> 250) and to prevent selection and induction of resistance (> 100). For vancomycin used in treatment of methicillin-resistant Staphylococcus aureus pneumonia, a much higher AUIC (400) is suggested to avoid treatment failure. For resistant gram-negative bacteria, such as Pseudomonas aeruginosa, the usual dosage of fourth-generation cephalosporins, carbapenems, and fluoroquinolones cannot achieve the target AUICs. Either combination therapy or higher dosage should be administered to achieve target AUICs and prevent the potential for failure. Unresolved issues, such as influence of protein binding, PK/PD at tissue sites versus blood, the impact of the immune system, should be addressed to refine the applicability of PK/PD in antibiotic treatment.
引用
收藏
页码:51 / 67
页数:17
相关论文
共 154 条
[1]   A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [J].
Ali, MZ ;
Goetz, MB .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :796-809
[2]   In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model [J].
Allen, GP ;
Cha, R ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2606-2612
[3]   Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit [J].
AlvarezLerma, F ;
Pellus, AM ;
Sanchez, BA ;
Ortiz, EP ;
Jorda, R ;
Barcenilla, F ;
Maravi, E ;
Galvan, B ;
Palomar, M ;
Serra, J ;
Bermejo, B ;
Mateu, A ;
Quintana, E ;
Palacios, MS ;
Giral, R ;
Gonzalez, V ;
Lerma, FA ;
Mesa, JL ;
Melgarejo, JA ;
Martinez, J ;
Insausti, J ;
Olaechea, P ;
Chanovas, M ;
Gilabert, A ;
Junquera, C ;
Valles, J ;
Palacios, F ;
Calvo, R ;
Mesalles, E ;
Nava, J ;
Santos, A ;
Armengol, S ;
Marzo, D .
INTENSIVE CARE MEDICINE, 1996, 22 (05) :387-394
[4]   Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime [J].
Ambrose, PG ;
Owens, RC ;
Garvey, MJ ;
Jones, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :445-453
[5]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[6]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[7]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[8]   In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379
[9]  
ANDES D, 1999, INF DIS SOC AM ANN M
[10]   A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides [J].
Bailey, TC ;
Little, JR ;
Littenberg, B ;
Reichley, RM ;
Dunagan, WC .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :786-795